Related Experiment Video

Updated: Aug 10, 2026

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Evolving MS criteria and the interpretation of research

Afsaneh Shirani1, Benjamin M Segal2,3, Olaf Stuve4,5,6

  • 1Department of Neurology, Saint Luke's Marion Bloch Neuroscience Institute, University of Missouri-Kansas City, Kansas City, MO, USA.

Therapeutic Advances in Neurological Disorders
|August 9, 2026
PubMed
Abstract

No abstract available in PubMed .

Keywords:
McDonald criteriabiomarkersclinical trialsdiagnostic criteriadisease classificationexternal validityhistorical cohortsmisclassification biasmultiple sclerosisresearch methodology

More Related Videos

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

Related Experiment Videos

Last Updated: Aug 10, 2026

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Diagnostic and Statistical Manual of Mental Disorders (DSM)01:27

Diagnostic and Statistical Manual of Mental Disorders (DSM)

The Diagnostic and Statistical Manual of Mental Disorders (DSM) serves as the primary classification system for mental health disorders, providing standardized diagnostic criteria for clinicians and researchers. First published by the American Psychiatric Association (APA) in 1952, the DSM has undergone several revisions to reflect evolving psychiatric understanding. The fifth edition, DSM-5, released in 2013, introduced key updates that expanded diagnostic categories and modified diagnostic...

Articles linked to this work by shared authors, journal, and citation graph.

Induced pluripotent stem cell treatment for microglia replacement in progressive MS.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Dynamics of Spinal Fluid Immune Cell Alterations Following Cladribine Tablet Treatment in Multiple Sclerosis.

Neurology(R) neuroimmunology & neuroinflammation·2026

Vedolizumab and the gut-CNS axis in multiple sclerosis: considering T cell licensing pathways.

Therapeutic advances in neurological disorders·2026

Clinical and radiological outcomes of directed treatment transitions from Gilenya® to generic fingolimod.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial.

Neurology·2025

Reporting patterns of multiple sclerosis with immune checkpoint inhibitors: analysis of the FDA Adverse Event Reporting System.

Therapeutic advances in neurological disorders·2025

Real-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study.

Therapeutic advances in neurological disorders·2026

Current practices in delirium prevention and treatment after acute stroke: results of a multicentre survey.

Therapeutic advances in neurological disorders·2026

Relapse risk and functional outcomes in anti-LGI1 encephalitis: A multicenter retrospective analysis.

Therapeutic advances in neurological disorders·2026

Evaluating the cognitive efficacy of marine-derived drugs in Alzheimer's disease: A systematic review and Bayesian network meta-analysis.

Therapeutic advances in neurological disorders·2026

Bilateral transcutaneous auricular nerve stimulation promotes motor function recovery after stroke: A randomized controlled trial.

Therapeutic advances in neurological disorders·2026

Perfusion-guided thrombolysis beyond 4.5 hours for acute ischemic stroke: A time-stratified systematic review and meta-analysis.

Therapeutic advances in neurological disorders·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us